IPO mar­ket con­tin­ues to churn with a pair of Covid-19 biotechs seek­ing Nas­daq, while mi­to­chon­dria-fo­cused Re­neo de­buts

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Biotech con­tin­ues to see a huge flow of com­pa­nies look­ing to make their pub­lic de­buts as the sec­ond quar­ter gets un­der­way.

Two Eu­ro­pean biotechs work­ing on Covid-19 vac­cines, Vac­citech and Val­ne­va, both filed their SEC pa­per­work over the week­end, while mi­to­chon­dr­i­al dis­ease com­pa­ny Re­neo Phar­ma­ceu­ti­cals priced its own IPO last Fri­day. Per End­points News’ tal­ly, the IPO count this year has now sur­passed 40 biotechs that have priced or filed, rough­ly on pace to match 2020’s record of 92.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.